Cerebrolysin Neuropeptide improves learning and memory in patients with early to moderately severe dementia associated with Alzheimer’s disease and Post Traumatic Brain Disorder.
Posted November 14, 2019
2 min read Question: Does the Cerebrolysin Neuropeptide reverse the pathological changes that cccur in Alzheimer’s disease? Answer: Alzheimer’s disease does occur in some patients with Type 2 Diabetes. Actually, Alzheimer’s disease is thought to be a form of “Type 3 Diabetes” of the brain. Alzheimer’s disease affects the hippocampus, the area of the brain […]
Read More